GETI.B

210.2

-0.47%↓

CAMX

600.5

+3.36%↑

BIOAB

316

+3.95%↑

VITR

131.8

+0.84%↑

AMBEA

143.2

+3.32%↑

GETI.B

210.2

-0.47%↓

CAMX

600.5

+3.36%↑

BIOAB

316

+3.95%↑

VITR

131.8

+0.84%↑

AMBEA

143.2

+3.32%↑

GETI.B

210.2

-0.47%↓

CAMX

600.5

+3.36%↑

BIOAB

316

+3.95%↑

VITR

131.8

+0.84%↑

AMBEA

143.2

+3.32%↑

GETI.B

210.2

-0.47%↓

CAMX

600.5

+3.36%↑

BIOAB

316

+3.95%↑

VITR

131.8

+0.84%↑

AMBEA

143.2

+3.32%↑

GETI.B

210.2

-0.47%↓

CAMX

600.5

+3.36%↑

BIOAB

316

+3.95%↑

VITR

131.8

+0.84%↑

AMBEA

143.2

+3.32%↑

Search

Elekta AB

Открыт

56.15 0.27

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

55.65

Макс.

56.55

Ключевые показатели

By Trading Economics

Доход

94M

230M

Продажи

424M

4.1B

P/E

Средняя по отрасли

74.079

76.798

Прибыль на акцию

0.64

Дивидендная доходность

4.32

Рентабельность продаж

5.651

Сотрудники

4,484

EBITDA

20M

529M

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

4.32%

2.37%

Рыночная статистика

By TradingEconomics

Рыночная капитализация

4.9B

22B

Предыдущая цена открытия

55.88

Предыдущая цена закрытия

56.15

Elekta AB График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

18 дек. 2025 г., 23:54 UTC

Популярные акции

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 дек. 2025 г., 23:51 UTC

Отчет

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 дек. 2025 г., 23:39 UTC

Главные движущие силы рынка

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 дек. 2025 г., 22:57 UTC

Приобретения, слияния, поглощения

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 дек. 2025 г., 21:40 UTC

Отчет

Nike Sales Tick Up, But China Weakness Persists

18 дек. 2025 г., 23:45 UTC

Обсуждения рынка

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 дек. 2025 г., 23:37 UTC

Обсуждения рынка
Отчет

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 дек. 2025 г., 23:36 UTC

Обсуждения рынка

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 дек. 2025 г., 23:03 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 дек. 2025 г., 23:02 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 дек. 2025 г., 23:00 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 дек. 2025 г., 22:59 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 дек. 2025 г., 22:58 UTC

Приобретения, слияния, поглощения

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 дек. 2025 г., 22:57 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 дек. 2025 г., 22:56 UTC

Приобретения, слияния, поглощения

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 дек. 2025 г., 22:55 UTC

Отчет

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 дек. 2025 г., 21:59 UTC

Отчет

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 дек. 2025 г., 21:50 UTC

Обсуждения рынка
Отчет

Tech, Media & Telecom Roundup: Market Talk

18 дек. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

18 дек. 2025 г., 21:35 UTC

Отчет

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 дек. 2025 г., 21:31 UTC

Отчет

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Greater China Rev Down 17% >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q EPS 53c >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Apparel Rev $3.91B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Equipment Rev $550M >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q N Amer Rev $5.63B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Footwear Rev $7.66B >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 дек. 2025 г., 21:15 UTC

Отчет

Nike 2Q Greater China Rev $1.42B >NKE

Сравнение c конкурентами

Изменение цены

Elekta AB Прогноз

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
help-icon Live chat